 Zacks Investment Research upgraded shares of Galera Therapeutics NASDAQ:GRTX from a hold rating to a buy rating in a research note published on Wednesday morning, Zacks.com reports. Zacks Investment Research currently has 12.00 target price on the stock. According to Zacks, Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and ... 